New Delhi: As coronavirus vaccine testing continues at a rapid pace, there is increasing expectation that an approved vaccine will be available in the Indian market by early 2021. Bernstein said this in a report.
Four vaccines are being worked on quickly
There are currently four potential vaccines worldwide that are expected to be approved in late 2020 or early 2021. Two of these vaccines were selected as partners by ‘AstraZeneca and Oxford’s Vaccine Against Viral Vectors’ and’ Novavax ‘Protein Subunit Vaccine’.
According to the report, first and second stage tests appear to be reliable in increasing the safety and immune response potential for these two vaccines. We are optimistic that an approved vaccine will be available in India in the first quarter of 2021.
Bernstein said the cost of the vaccine could be three to six dollars (Rs 225-550) per dose and collective immunity could take up to two years to develop due to implementation difficulties. The reason for this is the lack of experience regarding mass vaccination.
Read this too – be careful! Fake communications are sent to these states on behalf of ED. Do you know what is going on
According to the report, India has had two experiences with large-scale vaccination. One was the 2011 Polia Eradication Campaign and the other was the recent Indradhanush Intensive Mission (IMI), but its level was a third of the level required for the Kovid-19.
India will face challenges
Bernstein said the number of cold stores and the shortage of skilled workers are two major challenges. Even if we assume that the implementation speed will be twice as fast as before, it will take 18 to 20 months for the government program to be implemented.
He said, “We believe vaccines will be made available to sensitive areas like health workers and people over 65 and so on first. After that, the vaccine can be given to the people who provide essential services and the economically poor.
According to the report, Novavax’s vaccine gives better results than AstraZeneca and Oxford. Both achieved good results in the first two phases and are now in the third phase. To do this, a person must give two doses 21 to 28 days apart.
India can produce a billion vaccine doses
Bernstein said the Serum Institute of India was ready to introduce the vaccine first. The Serum Institute has partnered with AstraZeneca as well as Oxford and Novavax to create their potential vaccines. It has the ability to make both a protein subunit and a vector viral vaccine. If necessary, the ability of both types can be increased by changing one type. We don’t see any obstacles in production.
He said, ‘The Serum Institute is also working on an additional one billion doses capacity. We estimate they can produce 60 crore cans in 2021 and 1 billion cans in 2022. 40 to 50 crore cans of these will be available for India in 2021.
In addition, three Indian companies, Zydus, Bharat Biotech and Biological e, are working on their own vaccines. These vaccines are in phase I and phase II studies.